<DOC>
	<DOC>NCT01104792</DOC>
	<brief_summary>The objective of this study is to evaluate the long-term safety, tolerability and pharmacokinetics of cariprazine in patients with schizophrenia.</brief_summary>
	<brief_title>Long-term Study of Cariprazine in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patients and corresponding caregivers who have provided informed consents prior to any study specific procedures Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for schizophrenia (paranoid type, disorganized type, catatonic type or undifferentiated type), as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) Patients with normal physical examination, laboratory, vital signs and electrocardiogram (ECG) Patients with a DSMIVTR diagnosis of schizoaffective disorder, schizophreniform disorder, bipolar I or bipolar II disorder, or psychotic disorders other than schizophrenia.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Acute Schizophrenia</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>